NPI: 1649209263 · MC DOWELL, KY 41647 · Emergency Medicine Physician · NPI assigned 07/03/2006
Authorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
| Authorized Official | HARRIS, HOLLIE (PRESIDENT AND CEO) |
| NPI Enumeration Date | 07/03/2006 |
Other providers sharing the same authorized official: HARRIS, HOLLIE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 76,959 | $4.50M |
| 2019 | 66,966 | $3.49M |
| 2020 | 63,681 | $2.97M |
| 2021 | 77,371 | $3.86M |
| 2022 | 77,725 | $3.88M |
| 2023 | 74,304 | $4.24M |
| 2024 | 61,255 | $3.91M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 10,305 | 8,590 | $4.87M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3,063 | 2,707 | $2.17M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 16,013 | 14,093 | $1.80M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 25,797 | 16,211 | $1.79M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3,249 | 2,338 | $1.72M |
| G0378 | Hospital observation service, per hour | 3,012 | 1,444 | $1.36M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 22,274 | 17,689 | $1.14M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7,442 | 1,957 | $789K |
| 80053 | Comprehensive metabolic panel | 31,123 | 21,633 | $743K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1,022 | 694 | $618K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 31,151 | 23,792 | $615K |
| 70450 | Computed tomography, head or brain; without contrast material | 1,996 | 1,735 | $605K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5,233 | 4,752 | $388K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 29,202 | 23,234 | $379K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 14,448 | 7,316 | $361K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 6,038 | 3,869 | $338K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6,079 | 5,565 | $330K |
| 36415 | Collection of venous blood by venipuncture | 59,137 | 27,379 | $328K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2,543 | 1,690 | $311K |
| 87631 | 2,964 | 2,749 | $302K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5,020 | 4,603 | $287K |
| 71045 | Radiologic examination, chest; single view | 5,809 | 4,950 | $278K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6,132 | 3,135 | $272K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2,491 | 1,306 | $215K |
| 80061 | Lipid panel | 10,595 | 9,643 | $205K |
| 84484 | 5,656 | 4,408 | $202K | |
| 84443 | Thyroid stimulating hormone (TSH) | 12,010 | 10,985 | $197K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3,195 | 1,733 | $194K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 6,888 | 6,156 | $192K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2,808 | 1,014 | $182K |
| 71046 | Radiologic examination, chest; 2 views | 2,951 | 2,350 | $177K |
| 87040 | 2,578 | 1,885 | $142K | |
| 82607 | 6,409 | 5,886 | $141K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 5,625 | 4,307 | $119K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 3,890 | 3,634 | $113K |
| 81001 | 12,333 | 10,632 | $113K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 9,995 | 9,194 | $107K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 8,492 | 6,810 | $103K |
| 83880 | 2,389 | 1,871 | $101K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 4,829 | 4,106 | $98K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1,053 | 393 | $98K |
| 80074 | 1,378 | 1,238 | $98K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1,604 | 1,369 | $92K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 5,212 | 4,777 | $87K |
| 72100 | 954 | 829 | $84K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 3,099 | 2,519 | $79K |
| 83690 | 3,079 | 2,683 | $61K | |
| 81025 | 2,035 | 1,807 | $60K | |
| 83735 | 6,985 | 6,088 | $59K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 105 | 93 | $54K |
| 83605 | 1,744 | 1,385 | $51K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 228 | 205 | $51K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 756 | 417 | $49K |
| 82746 | 1,973 | 1,785 | $49K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3,323 | 2,965 | $45K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 309 | 269 | $45K |
| 72131 | 101 | 90 | $45K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2,733 | 2,263 | $42K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 164 | 154 | $41K |
| 87186 | 1,803 | 1,582 | $41K | |
| 96376 | 1,077 | 575 | $39K | |
| 82728 | 1,824 | 1,661 | $38K | |
| 73630 | 481 | 432 | $38K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 704 | 663 | $38K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1,042 | 947 | $37K |
| 82150 | 2,374 | 2,100 | $36K | |
| 82553 | 1,312 | 1,114 | $36K | |
| 82550 | 2,234 | 1,871 | $34K | |
| 83540 | 2,916 | 2,693 | $32K | |
| 71250 | 90 | 80 | $31K | |
| 82043 | 3,121 | 2,863 | $31K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,575 | 1,401 | $30K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 83 | 75 | $29K |
| 83550 | 2,181 | 2,033 | $29K | |
| 73564 | 339 | 276 | $29K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 854 | 738 | $29K |
| 84439 | 1,790 | 1,701 | $28K | |
| 73030 | 432 | 364 | $26K | |
| 87077 | 1,287 | 958 | $26K | |
| 97162 | 376 | 345 | $25K | |
| 82652 | 815 | 728 | $25K | |
| 73610 | 283 | 254 | $24K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 2,475 | 1,917 | $24K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 249 | 201 | $23K |
| 93041 | 878 | 749 | $19K | |
| 73562 | 263 | 222 | $19K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 31 | 25 | $19K |
| 0100U | 144 | 136 | $18K | |
| 83525 | 1,074 | 1,008 | $18K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 225 | 79 | $18K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 624 | 543 | $17K |
| 87522 | Neg quan hep c or qual rna | 412 | 368 | $17K |
| 87076 | 1,181 | 838 | $17K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 15 | 14 | $13K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 775 | 700 | $13K |
| 85378 | 623 | 505 | $13K | |
| 85610 | 1,339 | 1,101 | $12K | |
| 84703 | 493 | 466 | $11K | |
| 74022 | 84 | 72 | $11K | |
| 85730 | 647 | 526 | $10K | |
| 82803 | 135 | 111 | $10K | |
| 86038 | 719 | 661 | $10K | |
| 82570 | 1,096 | 1,054 | $10K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 1,202 | 356 | $10K |
| 86200 | 637 | 591 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 105 | 62 | $8K |
| 87070 | 336 | 272 | $8K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 182 | 134 | $8K |
| 74018 | 106 | 102 | $8K | |
| 73130 | 104 | 98 | $8K | |
| 84481 | 231 | 209 | $7K | |
| 84100 | 825 | 784 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 3,225 | 2,679 | $7K |
| 36600 | 183 | 135 | $6K | |
| 85652 | 758 | 669 | $6K | |
| 99406 | 607 | 551 | $6K | |
| 72040 | 70 | 65 | $5K | |
| 0002A | 425 | 406 | $5K | |
| 84145 | 70 | 60 | $5K | |
| 90686 | 249 | 215 | $5K | |
| 0001A | 495 | 466 | $5K | |
| 73110 | 55 | 51 | $4K | |
| 86140 | 259 | 195 | $4K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 300 | 241 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 131 | 127 | $4K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | 12 | 12 | $4K |
| 87581 | 83 | 75 | $4K | |
| 87486 | 83 | 75 | $4K | |
| 80076 | 230 | 200 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 13 | 13 | $3K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 104 | 100 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,178 | 760 | $3K |
| 97533 | 52 | 24 | $3K | |
| 84550 | 302 | 284 | $2K | |
| 84436 | 122 | 119 | $2K | |
| 84403 | 106 | 92 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 57 | 56 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 78 | 74 | $2K |
| 81002 | 363 | 279 | $2K | |
| 92523 | 13 | 13 | $2K | |
| 73080 | 17 | 16 | $2K | |
| 84480 | 63 | 63 | $2K | |
| 83615 | 81 | 55 | $2K | |
| 86431 | 210 | 194 | $1K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 71 | 69 | $1K |
| 84153 | 53 | 51 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 694 | 578 | $1K |
| 87590 | 53 | 53 | $1K | |
| 85384 | 55 | 35 | $1K | |
| 86677 | 46 | 41 | $1K | |
| 80069 | 203 | 115 | $983.87 | |
| 90674 | 48 | 43 | $967.81 | |
| 73502 | 14 | 12 | $958.07 | |
| 90715 | 13 | 13 | $811.09 | |
| 84270 | 43 | 39 | $800.67 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 124 | 91 | $696.66 |
| 86696 | 39 | 35 | $679.07 | |
| 86702 | 62 | 60 | $595.42 | |
| 90656 | 29 | 26 | $595.31 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 198 | 166 | $563.72 |
| 86756 | 24 | 22 | $528.29 | |
| 87634 | 19 | 16 | $432.18 | |
| 84146 | 25 | 24 | $427.38 | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24 | 24 | $426.89 |
| 86701 | 62 | 60 | $412.61 | |
| 87807 | 33 | 32 | $407.89 | |
| 0012A | 54 | 46 | $400.19 | |
| 86695 | 39 | 35 | $378.01 | |
| 85379 | 34 | 28 | $368.95 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 18 | 15 | $308.22 |
| 84402 | 15 | 13 | $302.40 | |
| 99497 | 15 | 13 | $295.86 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 13 | 13 | $285.52 |
| 0011A | 45 | 38 | $269.29 | |
| 88142 | 12 | 12 | $252.60 | |
| 0003A | 23 | 22 | $252.12 | |
| 86803 | 19 | 18 | $228.93 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 37 | 31 | $210.96 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 15 | 12 | $171.61 |
| 82140 | 57 | 16 | $157.13 | |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 13 | 12 | $138.40 |
| 80143 | 15 | 13 | $125.61 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 24 | 14 | $108.35 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | 12 | $95.08 |
| 82248 | 18 | 13 | $60.79 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 14 | 12 | $14.35 |
| A9270 | Non-covered item or service | 186 | 59 | $11.62 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 225 | 201 | $0.22 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 181 | 172 | $0.09 |
| Q0247 | Injection, sotrovimab, 500 mg | 13 | 13 | $0.03 |
| Q0222 | Injection, bebtelovimab, 175 mg | 12 | 12 | $0.00 |